| Literature DB >> 33747833 |
Leila Karimi1, Mitra Mahdavian2, Somayeh Makvandi3.
Abstract
BACKGROUND: Numerous studies have been conducted on the effect of acupressure on labor pain, some of which have reported conflicting results. Thus, the present study was performed to critically review the previous studies related to the effect of acupressure administered during labor for relieving labor pain.Entities:
Keywords: Acupressure; labor pain; pain management; parturition
Year: 2020 PMID: 33747833 PMCID: PMC7968589 DOI: 10.4103/ijnmr.IJNMR_257_19
Source DB: PubMed Journal: Iran J Nurs Midwifery Res ISSN: 1735-9066
Figure 1PRISMA* Flow chart of the study. *PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Quality of published clinical trial reports on the effect of physical activity on the severity of dysmenorrhea using the CONSORT* 2017 tool
| Section/Topic item | Checklist Item No. | CONSORT item | Reported No. (%) | Not reported No. (%) |
|---|---|---|---|---|
| Title and abstract | 1a | Identification as a randomized trial in the title | 8 (26.67%) | 22 (73.33%) |
| 1b | Structured summary of trial design, methods, results, and conclusions | 28 (93.33%) | 2 (6.67%) | |
| Introduction: | ||||
| Background and objectives | 2a | Background | 30 (100%) | 0 (0%) |
| 2b | Objectives | 19 (63.33%) | 11 (36.67%) | |
| Methods: | ||||
| Trial design | 3a | Description of trial design | 30 (100%) | 0 (0%) |
| 3b | Important changes to methods after trial commencement | 4 (13.33%) | 26 (86.67%) | |
| Participants | 4a | Eligibility criteria | 28 (93.33%) | 2 (6.67%) |
| 4b | Settings and locations | 30 (100%) | 0 (0%) | |
| Intervention (s) | 5a | The interventions for each group | 30 (100%) | 0 (0%) |
| 5b | Different interventions components | 20 (66.67%) | 10 (33.33%) | |
| 5c | How the interventions were standardized | 23 (76.67%) | 7 (23.33%) | |
| 5d | How adherence of care providers to the protocol was assessed | 9 (30%) | 21 (70%) | |
| 5e | How adherence of participants to interventions was assessed | 17 (56.67%) | 13 (43.33%) | |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures | 22 (73.33%) | 8 (26.67%) |
| 6b | Any changes to trial outcomes after the trial commenced | 14 (46.67%) | 16 (53.33%) | |
| Sample size | 7a | How sample size was determined | 7 (23.33%) | 23 (76.67%) |
| 7b | Interim analyses and stopping guidelines | 2 (6.67%) | 28 (93.33%) | |
| Randomization: | ||||
| Sequence generation | 8a | Random allocation sequence | 16 (53.33%) | 14 (46.67%) |
| 8b | Type of randomization | 14 (46.67%) | 16 (53.33%) | |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence, describing any steps taken to conceal the sequence | 9 (30%) | 21 (70%) |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 10 (33.33%) | 20 (66.67%) |
| Blinding | 11a | If done, who was blinded after assignment to interventions | 5 (16.67%) | 25 (83.33%) |
| 11b | Description of the similarity of interventions | 21 (70%) | 9 (30%) | |
| 11c | If blinding was not possible, description of any attempts to limit bias | 9 (30%) | 21 (70%) | |
| Statistical methods | 12a | Statistical methods used to compare groups | 16 (53.33%) | 14 (46.67%) |
| 12b | Additional analyses | 12 (40%) | 18 (60%) | |
| Results: | ||||
| Participant flow | 13a | The numbers of participants who were randomly assigned, received intended treatment, and were analyzed | 27 (90%) | 3 (10%) |
| 13b | Losses and exclusions | 8 (26.67%) | 22 (73.33%) | |
| 13c | For each group, the delay between randomization and the initiation of the intervention | 11 (36.67%) | 19 (63.33%) | |
| Recruitment | 14a | Defining the periods of recruitment and follow-up | 26 (86.67%) | 4 (13.33%) |
| 14b | Why the trial ended or was stopped | 21 (70%) | 9 (30%) | |
| Baseline data | 15 | A table for baseline demographic and clinical characteristics | 14 (46.67%) | 16 (53.33%) |
| Numbers analyzed | 16 | Number of participants | 19 (63.33%) | 11 (36.67%) |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | 26 (86.67%) | 4 (13.33%) |
| 17b | Effect sizes for binary outcomes | 10 (33.33%) | 20 (66.67%) | |
| Ancillary analyses | 18 | Results of any other analyses performed | 11 (36.67%) | 19 (63.33%) |
| Harms | 19 | All important harms or unintended effects | 3 (10%) | 27 (90%) |
| Discussion: | ||||
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 15 (50%) | 15 (50%) |
| Generalizability | 21 | Generalizability (external validity, applicability) | 19 (63.33%) | 11 (36.67%) |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 24 (80%) | 6 (20%) |
| Other information | ||||
| Registration | 23 | Registration number | 6 (20%) | 24 (80%) |
| Protocol | 24 | Full trial protocol access | 2 (6.67%) | 28 (93.33%) |
| Funding | 25 | Sources of funding | 9 (30%) | 21 (70%) |
*Consolidated Standards of Reporting Trials
Figure 2Percentage of risk of bias in each domain in all included studies
Figure 3Forest plot of the meta-analysis